ArticleArthritis care & research2026
The Association of Osteoarthritis With De Novo Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
objectiveWe aim to identify risk factors to enable stratification of patients' susceptibility to inflammatory arthritis immune-related adverse events (IA-irAEs). This retrospective study mainly examines whether preexisting osteoarthritis (OA) increases the likelihood of de novo IA-irAEs.
methodsThe prevalence of OA among immune checkpoint inhibitor (ICI)-treated patients who developed IA-irAE, those who developed other types of irAEs but not IA (non-IA irAEs), and those who did not develop any irAEs (non-irAEs) were compared. Electronic medical records were reviewed to extract demographic, clinical, and laboratory data. Group comparisons and logistic regression analyses were performed.
resultsA total of 181 de novo IA-irAE patients, 140 non-IA irAE patients, and 170 non-irAE patients were included. The prevalence of OA was significantly higher in the IA-irAE group (69%) than in the non-IA irAE group (48%) and the non-irAE group (48%) (both P < 0.001). The IA-irAE group demonstrated a higher frequency of multisite OA, with more predominant hand involvement (62%) than the non-IA irAE with OA group (13%) and the non-irAE with OA group (13%) (both P < 0.001). A family history of autoimmune disease (AID) (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.02-4.05), preexisting OA (OR 2.88, 95% CI 1.85-4.52), and melanoma (OR 2.63, 95% CI 1.56-4.47) were identified as risk factors for the development of IA-irAE.
conclusionOA was more prevalent among ICI-treated patients developing IA-irAE than those who were not. Hand OA was the most common OA pattern in IA-irAE patients. Preexisting OA, melanoma, and a family history of AID were associated with IA-irAE.
Identifiers
42223227What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.